Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
Source: CNBC · Oct 24, 2026
Share
The Money Angle
Business relevance
4/10
- 01Amgen says its drug, combined with an AstraZeneca immunotherapy, reduced the risk of death by 58% in patients with an aggressive lung cancer.
- 02The treatment result involves products from both drugmakers, but the source gives no pricing, revenue projections or commercial deal terms.
- 03No stock impact or implications specific to Black businesses or consumers are reported.
Share
Original reportingRead the full story at CNBC →This Money Angle is an AI-assisted summary of reporting by CNBC. Figures come only from the source article. Not financial advice.